Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography.

Senéterre, E; Taourel, Patrice; Bouvier, Yves; Pradel, J.; Beers, Bernard E. Van; Daurès, Jean‐Pierre; Pringot, Jacques; Mathieu, Didier; Jm, Bruel

doi:10.1148/radiology.200.3.8756932

Cited by 303 publications

(162 citation statements)

References 0 publications

Supporting

Mentioning

140

Contrasting

Unclassified

Order By: Relevance

“…Since superparamagnetic Fe 3 O 4 nanoparticles can enhance the alterations of proton relaxation in the tissue microenvironment, these are suitable as T 2 contrast agent in MRI [13,14]. These T 2 contrast agents cause to decrease the signal intensity in the region that they are accumulated, and hence cause negative contrast and provide a dark state in the image where the compounds are accumulated [15]. However, the direct use of magnetic nanoparticles as in vivo MRI contrast agent results in biofouling of the particles in blood plasma and formation of aggregates that are quickly sequestered by cells of the reticular endothelial system (RES) such as macrophages [16,17].…”

Section: Introductionmentioning

confidence: 99%

“…These results indicate that the PVP-grafted MNPs have great potential for application in MRI as a T2 contrast agent. Vol.4, No.6 (2010) 329-338 Available online at www.expresspolymlett.com DOI: 10.3144/expresspolymlett.2010.42 region that they are accumulated, and hence cause negative contrast and provide a dark state in the image where the compounds are accumulated [15]. However, the direct use of magnetic nanoparticles as in vivo MRI contrast agent results in biofouling of the particles in blood plasma and formation of aggregates that are quickly sequestered by cells of the reticular endothelial system (RES) such as macrophages [16,17].…”

mentioning

confidence: 99%

See 1 more Smart Citation

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Arsalani¹,

Fattahi²,

Nazarpoor³

2010

Express Polym. Lett.

231

View full text Add to dashboard Cite

Abstract. The magnetite (Fe3O4) nanoparticles (MNPs) coated with poly(N-vinyl pyrrolidone) (PVP) via covalent bonds were prepared as T2 contrast agent for magnetic resonance imaging (MRI). The surface of MNPs was first coated with 3-(trimethoxysilyl) propyl methacrylate (silan A) by a silanization reaction to introduce reactive vinyl groups onto the surface, then poly(N-vinyl pyrrolidone) was grafted onto the surface of modified-MNPs via surface-initiated radical polymerization. The obtained nanoparticles were characterized by FT-IR (Fourier transform infrared spectroscopy), XRD (X-ray diffraction), TEM (transmission electron microscopy), VSM (vibrating sample magnetometer), and TGA (thermogravimetric analysis). The MNPs had an average size of 14 nm and exhibited superparamagnetism and high saturation magnetization at room temperature. T2-weighted MRI images of PVP-grafted MNPs showed that the magnetic resonance signal is enhanced significantly with increasing nanoparticle concentration in water. The r1 and r2 values per millimole Fe, and r2/r1 value of the PVP-grafted MNPs were calculated to be 2.6 , 72.1, and 28.1(mmol/l) -1 ·s -1 , respectively. These results indicate that the PVP-grafted MNPs have great potential for application in MRI as a T2 contrast agent. Vol.4, No.6 (2010) 329-338 Available online at www.expresspolymlett.com DOI: 10.3144/expresspolymlett.2010.42 region that they are accumulated, and hence cause negative contrast and provide a dark state in the image where the compounds are accumulated [15]. However, the direct use of magnetic nanoparticles as in vivo MRI contrast agent results in biofouling of the particles in blood plasma and formation of aggregates that are quickly sequestered by cells of the reticular endothelial system (RES) such as macrophages [16,17]. Furthermore, aggregated nanoparticles change their superparamagnetic response [7]. Therefore, in order to minimize biofouling and aggregation of particles and escape from the RES for longer circulation times, the nanoparticles are usually coated with a layer of hydrophilic and biocompatible polymer such as dextran [18], dendrimers [19], poly(ethylene glycol) (PEG) [20], and poly(vinyl pyrrolidone) (PVP) [21][22][23]. Of synthetic polymers, PVP is water-soluble, non-charged, non-toxic, and is used in various medical applications [24]. While there is a potential concern about covalent interaction between hydrophilic polymers and magnetic nanoparticles in order to increase their stability in physiological medium [25][26][27][28][29], PVP coating on Fe 3 O 4 nanoparticles in all previous works has been achieved through noncovalent interaction. Now, polymers grafting of magnetic nanoparticles is one of the most attractive methods of surface modification [30,31]. In the present study, we carried out chemical synthesis and characterization of PVP-functionalized magnetite (Fe 3 O 4 ) nanoparticles. Since the PVP was bonded to the surface of magnetite nanoparticles through covalent bonds, the prepared magnetic fluid (ferrofluid) was ve...

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Arsalani¹,

Fattahi²,

Nazarpoor³

2010

Express Polym. Lett.

231

View full text Add to dashboard Cite

show abstract

“…9 MRI and CT have surpassed ultrasound as the tool of choice for the evaluation of human patients with focal hepatic or splenic lesions. 13 The lack of ionizing radiation, the overall safety of gadolinium as a contrast agent, and the inherently better soft tissue contrast associated with MRI are 3 important considerations for the preferential use of MRI instead of CT. [13][14][15][16][17][18][19][20][21]48,59,61,62 Numerous studies have documented the increased accuracy of MRI compared with iodinated contrast-enhanced CT scanning for the detection and characterization of hepatic lesions. [13][14][15][16][17][18][19][20][21]61,62 In people, lesions identified by abdominal ultrasound that are not confirmed by MRI generally are presumed to be artifacts of ultrasound scanning techniques.…”

Section: Discussionmentioning

confidence: 99%

Magnetic Resonance Imaging of Focal Splenic and Hepatic Lesions in the Dog

Clifford

Pretorius

Weisse

et al. 2004

Veterinary Internal Medicne

View full text Add to dashboard Cite

Focal hepatic and splenic lesions in the dog are common, and approximately half of such lesions are malignant. Both incidentally discovered lesions and lesions in patients with known malignancies represent diagnostic dilemmas. Ultrasound often fails to characterize such lesions adequately. This uncertainty may result in unnecessary splenectomies and liver biopsies for benign lesions or noncurative surgery for advanced-stage malignancies. In humans, ultrasound largely has been supplanted by computed tomography and magnetic resonance imaging (MRI) for the characterization of focal hepatic and splenic lesions. The inherently high soft tissue contrast of MRI allows the differentiation of benign from malignant hepatic and splenic lesions in the human patients. In this prospective study, 35 focal lesions of either the spleen (n ϭ 8) or the liver (n ϭ 27) were characterized by MRI in 23 dogs. Lesions were presumptively classified as malignant or benign on the basis of MRI findings. Imaging results then were correlated with histopathologic (29) or cytologic (6) evaluation of the lesions. The overall accuracy in differentiating malignant from benign lesions was 94% (33 of 35 lesions). The overall sensitivity and specificity were 100% (95% CI, 78-100%) and 90% (95% CI, 68-99%), respectively. MRI classified malignant hepatic lesions as hepatocellular carcinoma (HCC) in all confirmed cases and correctly predicted the histologic grade of 5 HCC lesions. These results suggest that MRI is a useful modality for abdominal imaging in veterinary patients, and MRI accurately differentiated benign from malignant focal hepatic and splenic lesions in this sample of patients.Key words: Abdominal imaging; Hemangiosarcoma; Hepatocellular carcinoma; Nodular hyperplasia.I n the canine liver, focal lesions may represent benign (eg, focal nodular hyperplasia [FNH] or regeneration, extramedullary hematopoiesis, cyst, abscess, hematoma) or malignant (eg, hepatocellular carcinoma [HCC], lymphosarcoma, malignant histiocytosis, hemangiosarcoma, metastatic carcinoma, metastatic sarcoma) processes. [1][2][3][4] Similarly, focal lesions in the spleen may be the result of benign (eg, lymphoid hyperplasia, cyst, abscess) or malignant (eg, hemangiosarcoma, metastatic sarcoma/carcinoma, malignant histiocytosis, lymphosarcoma) conditions. 5-8 These lesions traditionally have been identified by radiography or ultrasonography and commonly represent a diagnostic dilemma for the clinician, because each may require substantially different management. 1,2 Ultrasound is commonly used for abdominal imaging in veterinary medicine, but its ability to distinguish benign from malignant lesions in the liver and spleen is poor. 9-12 Consequently, unnecessary surgeries or biopsies may be performed on patients with benign lesions.In humans, the limitations of ultrasound are well recognized, and its role in specific patients is limited. Magnetic resonance imaging (MRI) provides soft tissue contrast that is far superior to that provided by either ultrasound or computed to...

show abstract

“…20,48 With the addition of contrast agents such as gadolinium, as well as the development of newer liver-specific contrast agents that use supraparamagnetic iron oxide particles, MRI may soon be able to detect even smaller liver metastases. [49][50][51] …”

Section: Evaluation Of the Patient With Hepatic Metastasesmentioning

confidence: 99%

Management of hepatic metastases

Choti

Bulkley

1999

Liver Transpl

View full text Add to dashboard Cite

Although the liver is the most common site of metastatic disease from a variety of tumor types, isolated hepatic metastases most commonly occur from colorectal cancer and, less frequently, from neuroendocrine tumors, gastrointestinal sarcoma, ocular melanoma, and others. Complete evaluation of the extent of metastatic disease, both intrahepatically and extrahepatically, is important before considering treatment options. Based on a preponderance of uncontrolled studies for hepatic metastatic colorectal carcinoma, surgical resection offers the only potential for cure of selected patients with completely resected disease, with 5-year survival rates of 25% to 46%. Systemic and hepatic arterial infusion chemotherapy may be useful treatment options in patients with unresectable disease and possibly as an adjuvant treatment after liver resection. Other techniques of local tumor ablation, including cryotherapy and radiofrequency ablation, although promising, remain unproved. Management of hepatic metastases from neuroendocrine tumors and other noncolorectal primary tumors should be individualized based on the patient's clinical course, extent of disease, and symptoms. Copyright 1999 by the American Association for the Study of Liver DiseasesA s many as 50% of the patients with a primary malignancy will eventually develop metastases in the liver, a percentage greater than for any other organ, including the lung. Although primary tumors that drain principally into the portal circulation are more likely than others to develop hepatic metastases, many tumors arising in other sites, such as the breast and lung, also commonly develop hepatic metastases. Although the liver represents a common site of spread from many of these solid tumors, isolated hepatic metastases most commonly occur from colorectal and neuroendocrine tumors. Other less common malignancies also can metastasize predominantly to the liver. For most other solid malignancies, the pattern of metastatic disease is most often that of generalized dissemination. Colorectal MetastasesCancer of the colon and rectum is the third most commonly diagnosed cancer in the United States. An estimated 131,600 new cases will have been discovered in 1998, comprising 11% of new cancer diagnoses. 1 An estimated 56,500 deaths will occur from colorectal cancer that year, comprising 10% of all cancer deaths. 1 Although mortality from largebowel cancer has been improving over the past 30 years, largely because of improvements in early detection, diagnosis, and treatment, approximately 50% of the patients with colorectal cancer eventually die of their neoplastic disease. 1 The liver is the most commonly involved organ in patients with metastatic colorectal cancer. Approximately 20% of these patients have clinically recognizable liver metastases at the time of their primary diagnosis. 1,2 After resection of a primary colorectal cancer in the absence of apparent metastatic disease, approximately 50% of the patients will subsequently manifest metastatic liver disease. Given these figures,...

show abstract

Detection of hepatic metastases: ferumoxides-enhanced MR imaging versus unenhanced MR imaging and CT during arterial portography.

Abstract: Ferumoxides-enhanced MR imaging is more accurate than unenhanced MR imaging and at least as accurate as CTAP for the detection of hepatic metastases.

Cited by 303 publications

References 0 publications

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Synthesis and characterization of PVP-functionalized superparamagnetic Fe3O4 nanoparticles as an MRI contrast agent

Magnetic Resonance Imaging of Focal Splenic and Hepatic Lesions in the Dog

Management of hepatic metastases

Contact Info

Product

Resources

About